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Next generation nucleic acid aptamers with two base 
modified nucleotides improve the binding affinity and 
potency  
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Aptamers are single-stranded oligonucleotides (RNA or DNA) 
that can bind to their targets with high affinities and specificities 
because of their ability to adopt three-dimensional shapes in 
solution [1]. Aptamers can be developed against a wide range of 
targets including small molecules, peptides, and whole cells, and 
can be developed in a standard molecular biology laboratory. 
Small size, low immunogenicity and thermo-stability make 
aptamers a promising tool for diagnostic and clinical 
applications. Traditionally, aptamers are developed by SELEX 
(Systematic Evolution of Ligands by Exponential enrichment), a 
reiterative process involving selection by target molecule 
incubation with an oligonucleotide library and enrichment of the 
selected oligonucleotides by amplification[1]. One drawback of 
current aptamer selection approach is the lack of diversity in the 
nucleic acid library with only four nucleobases compositions. In a 
recent study, Gawande et al. expanded the functional diversity 
of the starting oligonucleotide library by the introduction of 
pyrimidine nucleotides containing protein-like modifications at 
C5-position (Figure 1A)[2]. This is an extension of previous works 
using C5-modified uridines containing multiple protein-like 
modifications that culminated into the development of slow off-
rate modified aptamers (SOMAmers) for over 3000 proteins[2-7]. 
Furthermore, the efficacy of SELEX with a set of unmodified 
bases against a set of modified bases was compared, and the 
latter showed enhanced probability of selecting high affinity 
aptamers[6,7]. Gawande et al. took a step further by using 
libraries with two different modified pyrimidine nucleotides in 
SELEX involving two modifications on dC (Nap, Pp; Figure 1A) 
and five modifications on dU (Nap, Pp, Tyr, Moe, Thr; Figure 1A) 
in all possible pairwise combinations[2] (Figure 1B). The high 
performing aptamers with high binding affinity and specificity 
with nuclease resistance suitable for clinical applications were 
selected from libraries with two base modifications, and 
generally outperformed the isolated aptamers from libraries with 
single base modifications. This work presented by Gawande et 
al. and their previous works are important steps towards 
improving SELEX efficacy which can be readily adopted in most 
SELEX protocols today. 
 
Figure 1. Double base-modified aptamer development by SELEX. A) Each of 
the C5-base modified pyrimidine nucleotides: Nap, 5-[N-(1-
naphthylmethyl)carboxamide]-2′-deoxy; Pp, 5-[N-(phenyl-3-
propyl)carboxamide]-2′- deoxy; Moe, 5-[N-(1-morpholino-2-
ethyl)carboxamide]-2′-deoxy; Tyr, 5-[N-(4-hydroxyphenyl-2-
ethyl)carboxamide]-2′-deoxy; and Thr, 5-[N-(S-2-
hydroxypropyl)carboxamide]- 2′-deoxy. B) All pairwise combinations of 
modified bases including unmodified dC and dU as control. C) Schematic 
representation of SELEX used to enrich for high affinity aptamers. 
In this study, all possible pairwise combinations of modified and 
unmodified pyrimidines in the starting libraries (Figure 1B) were 
used to generate SOMAmers against a model target, human 
Proprotein convertase subtilisin/kexin type 9 (PCSK9). The 
aptamer selection method, using His-tagged paramagnetic 
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beads to immobilize PCSK9, does not really deviate from the 
traditional SELEX approach. However, the enrichment process 
had to be amended, as direct amplification of the modified 
libraries with modified pyrimidines was difficult. This problem 
was resolved by amplifying the selected modified 
oligonucleotides using unmodified nucleotide triphosphates, 
followed by primer extension of the newly synthesized dsDNA 
template with the triphosphate derivative of the modified bases 
to regenerate the selected aptamers using the KOD DNA 
polymerase (exo-)[3,8,9]. Although primer extension reaction with 
the modified bases had generally lower yield than the 
unmodified bases, there was no notable bias in the base 
composition of the starting libraries and therefore the approach 
had no adverse effects on the integrity of aptamer selection. 
Capitalizing on this, SELEX was performed using 18 different 
starting libraries and 6 selection cycles to generate enriched 
SOMAmers (Figure 1B, C). Preliminary results showed a 
general shift towards an enrichment of modified bases in 
libraries with one or two base modifications. Binding analysis of 
the selected sequences (40-mer oligonucleotides) showed the 
majority of high affinity SOMAmers were obtained from libraries 
with two base modifications. In particular, libraries with 
hydrophobic modifications on dC (Nap or Pp) together with Tyr-
dU produced high affinity SOMAmers with Kd values <0.1 nM, 
while libraries bearing only Pp-dC, Nap-dC or Tyr-dU did not 
produce ligands with similar affinities (Pp-dC/dU: >250 nM; Nap-
dC/dU: < 1 nM; dC/Tyr-dU: >10nM). The authors further 
truncated the high affinity SOMAmers (Kd < 1 nM) from 40 
nucleotides to 30 and showed that the libraries with two 
modifications containing Pp-dC retained the highest percentage 
of high affinity SOMAmers (60%) with Kd values up to 12 pM, 
compared to the libraries with single-modifications that showed 
only 21.5% retention. Based on the obtained binding affinity 
values, it is clear that most libraries with two modified bases 
yielded high affinity aptamers far better than libraries with single 
base modification as shown in Table 1. 
 
 
Table 1. Binding affinities of representative SOMAmers. Unless specified, 
all SOMAmers are 30-mers. 
Modified DNA library Kd 
Pp-dC/Tyr-dU 701 – 12 pM 
Pp-dC/dU > 250 nM (40-mer) 
Tyr-dUdU > 10 nM (40-mer) 
Pp-dC/Nap-dU 800 – 69 pM 
Pp-dC/dU > 250 nM (40-mer) 
dC/Nap-dU 223 pM 
Pp-dC/Pp-dU 564 – 53 pM 
Pp-dC/dU > 250 nM (40-mer) 
dC/Pp-dU > 5 nM (40-mer) 
Nap-dC/Tyr-dU 805 – 191 pM 
Nap/dC/dU 150 pM 
dC/Tyr-dU >10 nM (40-mer) 
Nap-dC/Pp-dU 379 – 68 pM 
Nap-dC/dU 150 pM 
dC/Pp-dU > 5 nM (40-mer) 
Nap-dC/Nap-dU 609 – 144 pM 
Nap-dC/dU 150 pM 
dC/Nap-dU 223 pM 
 
 
The selected SOMAmers not only showed high binding 
affinities, but also displayed high specificity as well. The 
specificity of the enriched SOMAmers were tested and showed 
no binding affinity to other closely related human proprotein 
convertases (PCs) such as PCSK1, PCSK2, furin, PCSK4, or 
PCSK7 (13.5–16.2% identity to PCSK9) at concentrations up to 
100 nM. In a cross-species binding assay using monkey PCSK9 
showed comparable affinity with human PCSK9, and some of 
the ligands also bound to rat and mouse PCSK9 (12% and 15% 
identify to PCSK9 respectively) with Kd values below 45 nM, all 
of which were derived from libraries containing two modified 
bases. It should be noted that cross-species reactivity is not an 
indication of loss of specificity, but demonstrates that the 
selected double-modified SOMAmers specifically binds to 
conserved motifs on the protein target. In addition, the cross-
species reactivity of the selected SOMAmers also does not 
suggest that we should overlook specialized selection protocols 
that specifically generate species cross-reactive aptamers such 
as toggle-SELEX[10]. 
The use of two modified bases in SELEX enabled the 
selection of SOMAmers with enhanced epitope coverage and 
facilitated the development of SOMAmer sandwich assays, 
which was particularly impressive as there was no need to direct 
the ligands to different binding sites, as is the case with 
multivalent aptamer isolation (MAISELEX) and array-based 
discovery platform for multivalent aptamers (AD-MAP)[11,12]. The 
authors identified SOMAmer pairs in a multiplexed assay by 
testing 96 of the high affinity SOMAmers in all pairwise 
combinations (9,216 pairs in total)[13]. The results showed that 
the high signalling pairs had at least one SOMAmer with two 
base modifications. However, the majority of the high signalling 
pairs consisted of two SOMAmers with two base modifications.  
As expected for any high affinity aptamers, the reported 
SOMAmers demonstrated value as a diagnostic and therapeutic 
tool for hypercholesterolemia patients. Furthermore, the 
developed SOMAmer pairs were used in sandwich assays to 
detect high plasma levels of PCSK9 in samples from a group of 
patients on atorvastatin therapy (n = 42)[14]. In addition, over 
70% of the tested SOMAmers showed at least 90% inhibition of 
PCSK9 with IC50 values between 0.1–1 nM. Specifically, the 
SOMAmer with Pp-dC/Nap-dU modifications (SL1063) potently 
blocked LDL internalization by PCSK9 and its mutant form 
D374Y (IC50 = 2.8 nM and 35 pM, respectively). Although IC50 
for the mutant D374Y was 80-fold higher than the IC50 for wild-
type PCSK9, the binding affinity towards the mutant is only 3-
fold higher than the wild type (D374Y Kd = 5.2 pM; PCSK9 Kd = 
14.7 pM). The underlying mechanism behind this phenomenon 
remains to be elucidated, but the authors suggested that it could 
be related to the differences of steric or kinetic effects of the 
SOMAmers on both the mutant and wild-type PCSK9. 
The authors did a tremendous amount of work to identify the 
best combinations of two modified bases with 18 separate 
SELEX experiments. Indeed, the hydrophobic modifications 
Nap, Pp, and Tyr improved binding affinities, which is in 
agreement that hydrophobic aromatic side chains are critical for 
antibody paratopes[15,16]. In particular, the extended methylene 
linker in the Pp side chain in combination with a second base 
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modification is the key to high affinity binding for their combined 
capability to access deeper binding pockets. Despite the 
success in generating high affinity SOMAmers with cross-
species reactivity, it does not necessarily mean that we should 
ignore SELEX protocols dedicated to generating cross-reactive 
aptamers (toggle-SELEX). Similarly, the selected SOMAmers 
displayed some degree of nuclease resistance, but post-SELEX 
modifications remains an important step to further engineer the 
aptamers for specific purposes, such as modification on the 
sugar ring (e.g. LNA substitution[17,18]) to improve nuclease 
resistance and thermal stability, or modifications at the 3’ or 5’ 
caps to enhance bioavailability. The results obtained by 
Gawande et al. reinforce that enhancing the diversity of the 
starting library is indeed the next evolutionary step for SELEX, 
and should serve as an inspiration to find new ways to evolve 
aptamer selection methods. 
Acknowledgements  
RNV acknowledges funding support from the Department of 
Health (Merit Award), Western Australia; McCusker Charitable 
Foundation and Perron Institute for Neurological and 
Translational Science.  
Keywords: SELEX • aptamers • modified nucleotides • 
SOMAmer • PCSK9 
[1]. F. Lipi, S. Chen, M. Chakravarthy, S. Rakesh, R. N. Veedu, RNA 
biology 2016, 13, 1232-1245. 
[2]. B. N. Gawande, J. C. Rohloff, J. D. Carter, I. von Carlowitz, C. 
Zhang, D. J. Schneider, N. Janjic, Proc Natl Acad Sci U S A 2017, 
114, 2898-2903. 
[3]. J. D. Vaught, C. Bock, J. Carter, T. Fitzwater, M. Otis, D. 
Schneider, J. Rolando, S. Waugh, S. K. Wilcox, B. E. Eaton, 
Journal of the American Chemical Society 2010, 132, 4141-4151. 
[4]. U. A. Ochsner, E. Katilius, N. Janjic, Diagnostic microbiology and 
infectious disease 2013, 76, 278-285. 
[5]. D. R. Davies, A. D. Gelinas, C. Zhang, J. C. Rohloff, J. D. Carter, 
D. O'Connell, S. M. Waugh, S. K. Wolk, W. S. Mayfield, A. B. 
Burgin, T. E. Edwards, L. J. Stewart, L. Gold, N. Janjic, T. C. 
Jarvis, Proc Natl Acad Sci U S A 2012, 109, 19971-19976. 
[6]. L. Gold, D. Ayers, J. Bertino, C. Bock, A. Bock, E. N. Brody, J. 
Carter, A. B. Dalby, B. E. Eaton, T. Fitzwater, D. Flather, A. 
Forbes, T. Foreman, C. Fowler, B. Gawande, M. Goss, M. Gunn, 
S. Gupta, D. Halladay, J. Heil, J. Heilig, B. Hicke, G. Husar, N. 
Janjic, T. Jarvis, S. Jennings, E. Katilius, T. R. Keeney, N. Kim, T. 
H. Koch, S. Kraemer, L. Kroiss, N. Le, D. Levine, W. Lindsey, B. 
Lollo, W. Mayfield, M. Mehan, R. Mehler, S. K. Nelson, M. Nelson, 
D. Nieuwlandt, M. Nikrad, U. Ochsner, R. M. Ostroff, M. Otis, T. 
Parker, S. Pietrasiewicz, D. I. Resnicow, J. Rohloff, G. Sanders, S. 
Sattin, D. Schneider, B. Singer, M. Stanton, A. Sterkel, A. Stewart, 
S. Stratford, J. D. Vaught, M. Vrkljan, J. J. Walker, M. Watrobka, S. 
Waugh, A. Weiss, S. K. Wilcox, A. Wolfson, S. K. Wolk, C. Zhang, 
D. Zichi, PLoS One 2010, 5, e15004. 
[7]. J. C. Rohloff, A. D. Gelinas, T. C. Jarvis, U. A. Ochsner, D. J. 
Schneider, L. Gold, N. Janjic, Molecular therapy. Nucleic acids 
2014, 3, e201. 
[8]. J. C. Rohloff, C. Fowler, B. Ream, J. D. Carter, G. Wardle, T. 
Fitzwater, Nucleosides Nucleotides Nucleic Acids 2015, 34, 180-
198. 
[9]. M. Takagi, M. Nishioka, H. Kakihara, M. Kitabayashi, H. Inoue, B. 
Kawakami, M. Oka, T. Imanaka, Appl Environ Microbiol 1997, 63, 
4504-4510. 
[10]. R. White, C. Rusconi, E. Scardino, A. Wolberg, J. Lawson, M. 
Hoffman, B. Sullenger, Molecular therapy : the journal of the 
American Society of Gene Therapy 2001, 4, 567-573. 
[11]. Q. Gong, J. Wang, K. M. Ahmad, A. T. Csordas, J. Zhou, J. Nie, R. 
Stewart, J. A. Thomson, J. J. Rossi, H. T. Soh, Anal Chem 2012, 
84, 5365-5371. 
[12]. M. Cho, S. S. Oh, J. Nie, R. Stewart, M. J. Radeke, M. Eisenstein, 
P. J. Coffey, J. A. Thomson, H. T. Soh, Anal Chem 2015, 87, 821-
828. 
[13]. U. A. Ochsner, L. S. Green, L. Gold, N. Janjic, Biotechniques 
2014, 56, 125-128, 130, 132-123. 
[14]. S. G. Lakoski, T. A. Lagace, J. C. Cohen, J. D. Horton, H. H. 
Hobbs, The Journal of clinical endocrinology and metabolism 
2009, 94, 2537-2543. 
[15]. T. Ramaraj, T. Angel, E. A. Dratz, A. J. Jesaitis, B. Mumey, 
Biochimica et biophysica acta 2012, 1824, 520-532. 
[16]. J. V. Kringelum, M. Nielsen, S. B. Padkjaer, O. Lund, Molecular 
immunology 2013, 53, 24-34. 
[17]. R. N. Veedu, J. Wengel, Chemistry & biodiversity 2010, 7, 536-
542. 
[18]. R. N. Veedu, J. Wengel, RNA biology 2009, 6, 321-323. 
 
10.1002/cbic.201700276ChemBioChem
This article is protected by copyright. All rights reserved.
HIGHLIGHT          
For internal use, please do not delete. Submitted_Manuscript 
 
 
 
 
 
Entry for the Table of Contents (Please choose one layout) 
 
Layout 1: 
 
HIGHLIGHT 
Text for Table of Contents    Hadi AlShamaileh and Rakesh N. 
Veedu* 
Page No. – Page No. 
Next generation nucleic acid 
aptamers with two base modified 
nucleotides improve the binding 
affinity and potency  
  
 
 
 
Nucleic acid aptamers with high binding affinity, specificity, epitope coverage, and nuclease resistance 
were developed using novel oligonucleotide libraries containing two base-modified pyrimidine 
nucleotides.  
 
10.1002/cbic.201700276ChemBioChem
This article is protected by copyright. All rights reserved.
